drugset
Drugs / Gamma Glutamylcysteine
last change Jun 2026 re-read 3 minutes ago

Gamma Glutamylcysteine

also known as GGC · Gamma- Glutamylcusteine
Developed for
cognitive disorder · Parkinson disease
Investigated by
Pravat Mandal · Chuck Noll Foundation · Inid Research Lab · Robert J. Coury Family - Mylan Foundation · Waste Connections Inc

Trials 3

today NCT07583251 · Ph 1 NCT07050173 · Ph 1 NCT07064005 · Ph 1
2027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07583251 Jun 2026 → Jan 2027 expected cognitive disorder Pravat Mandal Recruiting No outcome recorded
Phase 1 NCT07050173 May 2026 → Nov 2027 expected — Pravat Mandal Recruiting No outcome recorded
Phase 1 NCT07064005 Mar 2026 → Sep 2027 expected Parkinson disease Pravat Mandal Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Gamma Glutamylcysteine “The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when...” NCT07583251 ↗
3

NCT07064005 ↗

NCT07050173 ↗

NCT07583251 ↗
Known as Gamma- Glutamylcusteine “Drug: Gamma- Glutamylcusteine” NCT07583251 ↗
Known as GGC “The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when...” NCT07583251 ↗
1

“Gamma-glutamylcysteine (GGC)” NCT07050173 ↗
Route Oral “400mg tablet orally (two times) per day.” NCT07050173 ↗